Spinal Muscular Atrophy (SMA)

About Spinal Muscular Atrophy (SMA)

Spinal muscular atrophy (SMA) is a hereditary disease that causes weakness and muscle wasting due to the loss of lower motor neurons that control movement1. This weakness and muscle wasting results from a lack of survival motor neuron (SMN) protein, which is critical for the maintenance of motor neurons. Ultimately, individuals with the most severe type of SMA can become paralysed and have difficulty performing the basic functions such as breathing and swallowing2

SMA is estimated to occur in 1 in 6,000 to 1 in 10,000 live births3. Its severity correlates with the amount of SMN protein. People with Type 1 SMA, the most severe life-threatening form, produce very little SMN protein and don’t live beyond two years old without respiratory support. People with Type 2 and Type 3 SMA produce greater amounts of SMN protein and have less severe, but still life-altering forms of SMA2

References 

1. FDA approves first drug for spinal muscular atrophy,
    FDA, Dec 2016.

2. U.S. FDA Approves Biogen’s SPINRAZA™ (nusinersen), The First Treatment for Spinal Muscular Atrophy,
    Biogen, Dec 2016.

3. Spinal muscular atrophy,
    D'Amico, A., et al., Orphanet Journal of Rare Diseases, 2011.

  1. Spinraza (nusinersen)
    Spinraza (nusinersen)
    by Biogen Idec Ltd
    for Spinal Muscular Atrophy
    €99,000.00
View as Grid List

1 Item

per page
Set Descending Direction

One more step before you can continue

Our service contains information about acquiring medicines that have been approved in another country. This includes professional information such as approval details, product information and pricing. By scrolling, you are declaring that you are requesting any such information.

Scroll down.

No, I'd like to receive general information only.

Disclaimer: The information TSM provides is aimed at patients with terminal and life-debilitating diseases, their doctors and healthcare professionals. It supports an informed decision by the treating doctor about the patient’s treatment and the consideration of a medicine which has not been approved in the patient’s country.